SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS |
The
following calculates basic and diluted EPS:
SCHEDULE
OF CALCULATIONS OF BASIC AND DILUTED EPS
| |
Three Months | | |
Three Months | |
| |
Ended | | |
Ended | |
| |
June 30, 2023 | | |
June 30, 2022 | |
(Loss) income from continuing operations, numerator, basic and diluted computation | |
$ | (3,869,732 | ) | |
$ | 10,660,028 | |
| |
| | | |
| | |
Weighted average common shares, basic | |
| 2,716,512 | | |
| 1,069,157 | |
Effect of series B warrants | |
| - | | |
| - | |
Effect of stock awards | |
| - | | |
| 2,128 | |
Effect of preferred stock | |
| - | | |
| 147,939 | |
Weighted average common shares, dilutive | |
| 2,716,512 | | |
| 1,219,224 | |
(Loss) earnings per common share – basic | |
$ | (1.42 | ) | |
$ | 9.97 | |
(Loss) earnings per common share – diluted | |
$ | (1.42 | ) | |
| 8.74 | |
| |
Six Months | | |
Six Months | |
| |
Ended | | |
Ended | |
| |
June 30, 2023 | | |
June 30, 2022 | |
(Loss) income from continuing operations | |
$ | (997,776 | ) | |
$ | 20,047,189 | |
Deemed dividend | |
| - | | |
| (6,930,335 | ) |
Net income continuing operations, numerator, basic computation | |
| (997,776 | ) | |
| 13,116,854 | |
Recognition and change in fair value of warrant liabilities | |
| - | | |
| (26,625,915 | ) |
Net loss continuing operations, numerator, diluted computation | |
$ | (997,776 | ) | |
$ | (13,509,061 | ) |
| |
| | | |
| | |
Weighted average common shares, basic | |
| 2,138,444 | | |
| 1,025,108 | |
Effect of series B warrants | |
| - | | |
| 43,128 | |
Weighted average common shares, dilutive | |
| 2,138,444 | | |
| 1,068,236 | |
Loss per common share – basic | |
| (0.47 | ) | |
| 12.80 | |
Loss per common share – diluted | |
$ | (0.47 | ) | |
$ | (12.65 | ) |
|
SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES |
Additionally,
the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common
share:
SCHEDULE
OF DILUTIVE NET LOSS PER COMMON SHARES
| |
June 30, 2023 | | |
June 30, 2022 | |
| |
For the Three Months Ended | |
| |
June 30, 2023 | | |
June 30, 2022 | |
Shares subject to outstanding common stock options | |
| 10,928 | | |
| 10,928 | |
Shares subject to outstanding Series A warrants | |
| 113,000 | | |
| 113,000 | |
Shares subject to outstanding Series F warrants | |
| 2,105,264 | | |
| - | |
Shares subject to placement agent warrants | |
| 52,632 | | |
| - | |
Shares subject to unvested stock awards | |
| 3,471 | | |
| - | |
Shares subject to conversion of Series B preferred stock | |
| - | | |
| - | |
Shares subject to warrant liability | |
| - | | |
| 668,299 | |
| |
June 30, 2023 | | |
June 30, 2022 | |
| |
For the Six Months Ended | |
| |
June 30, 2023 | | |
June 30, 2022 | |
Shares subject to outstanding common stock options | |
| 10,928 | | |
| 10,928 | |
Shares subject to outstanding Series A warrants | |
| 113,000 | | |
| 113,000 | |
Shares subject to outstanding Series F warrants | |
| 2,105,264 | | |
| - | |
Shares subject to placement agent warrants | |
| 52,632 | | |
| - | |
Shares subject to unvested stock awards | |
| 3,471 | | |
| 4,621 | |
Shares subject to conversion of Series B preferred stock | |
| - | | |
| 147,939 | |
Shares subject to warrant liability | |
| - | | |
| - | |
|